FNY Investment Advisers LLC Acquires 13,274 Shares of Kenvue Inc. (NYSE:KVUE)

FNY Investment Advisers LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 167.3% during the fourth quarter, HoldingsChannel reports. The fund owned 21,208 shares of the company’s stock after purchasing an additional 13,274 shares during the quarter. FNY Investment Advisers LLC’s holdings in Kenvue were worth $452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in KVUE. Acadian Asset Management LLC purchased a new stake in Kenvue during the 2nd quarter worth about $412,000. DekaBank Deutsche Girozentrale boosted its position in shares of Kenvue by 8.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 1,146,742 shares of the company’s stock valued at $20,742,000 after acquiring an additional 90,140 shares during the period. Meeder Advisory Services Inc. grew its stake in Kenvue by 40.6% during the second quarter. Meeder Advisory Services Inc. now owns 14,656 shares of the company’s stock valued at $266,000 after acquiring an additional 4,234 shares in the last quarter. Parallel Advisors LLC increased its holdings in Kenvue by 27.3% during the 2nd quarter. Parallel Advisors LLC now owns 25,936 shares of the company’s stock worth $472,000 after acquiring an additional 5,558 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in Kenvue by 7.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 5,721,005 shares of the company’s stock worth $104,008,000 after purchasing an additional 375,425 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.6 %

Shares of KVUE opened at $20.97 on Tuesday. The stock has a market capitalization of $40.20 billion, a P/E ratio of 38.13, a PEG ratio of 2.02 and a beta of 1.46. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $22.58 and a two-hundred day simple moving average of $21.63.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the company posted $0.31 EPS. Kenvue’s quarterly revenue was down .4% compared to the same quarter last year. On average, research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Jefferies Financial Group started coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.